Abstract Submission

Abstract Submission

The abstract submission is now closed and will be reopened in July 2021.

If you have already submitted an abstract or are preparing your abstract, we appreciate your efforts and we will be in touch with some alternative options for presenting your work to your fellow neuromodulators around the globe.

The INS Congress committees invite you to submit your abstract to the INS’s 15th World Congress. We welcome abstracts on a wide range of neuromodulation-related topics encompassing basic science, mechanisms of action, neural engineering, socioeconomics and global trends, emerging technologies, and translational and clinical research — including interventions for the brain, spine, and peripheral nerves.

 

GENERAL INFORMATION FOR MAIN INS CONGRESS ABSTRACT SUBMISSIONS 

In addition to traditional poster presentations, the INS will be displaying e-Posters at e-Poster stations. The  INS Scientific Program and Biennial Congress Committees have also reserved room on the program for free oral presentations. Each oral presenter will be allowed 8 minutes of lecture time, 8 slides, and a 2-minute question and answer period. The committee will accept a total of approximately 140-160 oral presentations.

Abstracts previously presented or published may not be submitted without modification. Original work must be changed or expanded, resulting in a new abstract.

 

SELECTION CRITERIA

Submissions will be reviewed and rated by members of the Scientific, Biennial Congress, and Education and CME Committees and Neuromodulation Editorial Board who have expertise in the clinical area to which the submission belongs. Each submission will be reviewed for its scientific or clinical importance, ethical practice, study design and conflict of interest. Any conflicts of interest must be resolved prior to an abstract’s acceptance.

The INS Scientific Program Committee recognizes that submissions of high quality, accepted for presentation at this meeting, should be acknowledged.  All accepted abstracts will be published on the Society’s website and in the online version of the INS journal, Neuromodulation: Technology at the Neural Interface. INS will retain the copyright of published abstracts.

 

NOTIFICATION OF PEER REVIEW OUTCOME

Notification of abstract acceptance or non-acceptance will be emailed to the person listed on the abstract as Presenting author late January 2021.

Industry employees’ participation as presenters in the scientific program is only allowed if they agree to speak only on completely non-commercial topics, unrelated to any of their company’s products, such as:

  • basic science research (e.g. pre-clinical research, or therapy discovery)
  • process or methodologies of research unrelated to a specific disease or device
  • mechanisms of action unrelated to a specific product

 

ABSTRACT SUBMISSION GUIDELINES

PRESENTATION TYPES AVAILABLE

ORAL COMMUNICATIONS

Refers to abstracts accepted for oral presentations at the podium in dedicated Oral Communication Sessions.
Please note: Abstracts that are accepted for Oral Communication sessions are automatically accepted as Posters / e-Posters as well.

PAPER POSTERS / E-POSTERS

Paper posters will be displayed on numbered poster boards in the Exhibition area to be viewed during the Congress. In addition, e-Posters will also be available at
e-Poster stations.

 

RULES FOR SUBMISSION

Please read the submission rules before submitting an abstract.

  • Abstracts must be submitted online via the website only.
    ABSTRACTS SUBMITTED BY EMAIL WILL NOT BE ACCEPTED.
  • Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.

 

LIMITATIONS

  • The same person may submit up to 4 abstracts regardless of presenting author.
  • The same person may serve as presenting author on up to 4 abstracts.
  • Presenting authors must be registered participants. Only accepted abstracts of authors who have paid their registration fees will be included in the Congress program.
  • Submission of the abstract constitutes the consent of all authors to publication (e.g. Congress and the INS society’s website, programs, other promotions, the INS’s journal, Neuromodulation: Technology at the Neural Interface, etc.)
  • The presenting author is required to ensure that all co-authors are aware of the content of the abstract and agree to its submission, before submitting the abstract.
  • The presenting author can be replaced by one of the abstract co-authors only.
  • Oral Communications and Posters are limited to one (1) primary presenter.
  • Abstracts must be original and not have been published or presented at any other congress prior to the 15th World Congress of the International Neuromodulation Society (INS)
  • The abstract must be submitted in good English.  Proofread for typographical, grammar, and syntax errors. The Scientific Committee reserves the right to reject those abstracts which are presented in poor English, or may request an immediate revision by the presenter.
  • COI and Financial Disclosures: Abstract submitters will be required to disclose conflicts of interests and financial disclosures in the submission system for both themselves and for all the authors.
  • Publication Embargo: The abstract contents will be available 2 weeks prior to the Congress.
  • Instructions for preparation of presentations will be made available on the congress website.

Before you begin, please prepare the following information:

PRESENTING AUTHOR`S CONTACT DETAILS:

  • Full first and family name(s)
  • Primary Qualification (Please click here to check the list of acronyms related to academic degree or honors.)
  • Email address
  • Affiliation details: department, institution / hospital, city, state (if relevant), Country
  • Phone number
  • Institution Affiliations: All department and institutional affiliations should be listed.

AUTHOR AND CO-AUTHORS’ DETAILS:

Authors should be entered in the order in which they should appear in print.

PREFERRED PRESENTATION TYPE:

  • Oral Communication (and Poster / e-Poster)
  • Or Poster / e-Poster only

 

ABSTRACTS SET UP AND CONTENT

 ABSTRACT TITLE

  • The title should be brief and reflect the content of the abstract (maximum 25 words) – Please use standard UPPER CASE letters
  • Do not use non-standard abbreviations
  • Commercial names may not be used in the abstract’s title (generic names only)
  • Do not put a full stop (.) at the end of the sentence

PLEASE SUBMIT ALL SYMBOLS AS WORDS

ABSTRACT TEXT:

Up to 400 words including acknowledgements. (Please note: word count is affected when graphs/tables are included). Please provide an accurate, succinct and informative representation of the content that will be presented in the poster, if accepted.

ABSTRACT TOPIC: 

Select the abstract topic per the list of topics.

IMAGES: 

The maximum file size of each image is 500 KB. The maximum pixel size of the graph/image is 600(w) x 800(h) pixel. You may upload images in JPG, PNG or GIF format only. Patient identity must be protected or written permission from the patient must accompany the print. 

ABSTRACT FORMAT:

  • Introduction
  • Methods/Materials
  • Results
  • Discussion
  • Conclusions
  • Supplemental Data
  • References
  • Acknowledgements
  • Learning Objectives

ABBREVIATIONS:

  • These may be used if standard or if spelled out and defined at the first use (put in parentheses immediately after the first mention of a term or phrase). Compounds should be mentioned with the generic name, in lower cases.
  • Commercial names are admitted in the Materials and Methods section only, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)”. Do not use the ampersand character (&) unless it is part of the company name. Compounds should be mentioned with the generic name, in lower cases.
  • Use generic names of devices and drugs. The presentation must be balanced and contain no commercial promotional content nor commercial logos.
  • Submissions may not contain patient names, hospital ID numbers or other identifying information.
  • If the cost of a presentation has been underwritten to any extent, a clear acknowledgement stating the support and identifying the source should be included in the abstract (e.g., “The support of [corporation or institution] for this project is gratefully acknowledged.”)

 

CONTENT WITHOUT COMMERCIAL BIAS

From ACCME Standards for Commercial Support 

  • The content of abstracts, posters and oral presentations must promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. Presentations must avoid commercialism and may not contain any logos, commercial branding or messaging.
  • Abstracts, posters and oral presentations must give a balanced view of therapeutic options. If the content includes trade names, where available, trade names from several companies should be used, not just trade names from a single company, and they should be limited to the material and methods section only. Generic terms contribute to impartiality, and should be used in title and in the body of the abstract.

 

COMMERCIAL INFLUENCE AND BIAS

From EACCME Criteria for the Accreditation of Live Educational Events (LEEs), General principles:

  • The education provided must be free of any commercial influence or bias;
  • The education provided must be free of any form of advertising;
  • Sponsorship must be under the form of an unrestricted educational grant;
  • LEEs provided entirely by a pharmaceutical or medical equipment industry will not be considered for accreditation.
  • All educational material must be free of any form of advertising and any form of bias.
  • The EACCME® will reject any application that, in its opinion, includes advertising of any product or company directly related to any educational material (essential criterion).
  • Specific examples that will lead to automatic rejection of an application include:
    • the use of a sponsor’s name in the title of the scientific program, a scientific session or a scientific  lecture;
    • the display of brand names and/or individual logos in scientific lectures or in the scientific program.

 

POLICY ON COMMERCIAL SUPPORT

Presentations that constitute promotion and advertising will not be accepted. If the cost of a presentation has been underwritten to any extent, a clear acknowledgement stating the support and identifying the source should be included in the abstract (e.g., “The support of [corporation or institution] for this project is gratefully acknowledged.”). Statements made in presentations are the sole responsibility of the author or presenter. Statements should not be viewed as or considered representative of any formal stance or position taken on any subject, issue, or product by the International Neuromodulation Society.

*From ACCME Standards for Commercial Support TM

 

IMPORTANT INFORMATION

  • The submission form allows you to store your abstract as a DRAFT until the deadline. After the deadline, if not submitted, drafts will be deleted.
  • Click on the SUBMIT button at the end of the process in order to save your abstract. You may log into the system later to make changes to your abstract, up until the submission deadline. After that deadline further changes will not be possible.
  • You will receive an abstract reference number via email after you have submitted your abstract. Please refer to this abstract number in all correspondence regarding the abstract.
  • Please contact us if you do not receive confirmation that your abstract has  been submitted.
  • Please do not submit multiple copies of the same abstract.
  • Click here for information about Late-breaking research abstracts
  • NOTIFICATIONS:
    Notification of abstract acceptance or non-acceptance will be emailed to the person listed on the abstract as Presenting author at the end of January 2021.

 

ABSTRACT SUBMITTER’S DECLARATION

During abstract submission you will be asked to confirm that you agree to the following:

  1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission and I am aware that it will be published exactly as submitted.
  2. Submission of the abstract constitutes the consent of all authors to publication (e.g. Congress and the INS society’s website, programs, other promotions, the INS’s journal, Neuromodulation: Technology at the Neural Interface, etc.)
  3. As the Abstract Submitter, I warrant on behalf of all authors and institutions that I am the sole owner or have the rights of all the information and content (“Content”) provided to the International Neuromodulation Society (INS) and Kenes Group (Hereafter: “The Organizers”). The publication of the abstract does not infringe any third-party rights including, but not limited to, intellectual property rights.
  4. As the Abstract Submitter, I grant the INS and the Organizers a royalty-free, perpetual, irrevocable nonexclusive license to use, reproduce, publish, translate, distribute, and display the Content.
  5. I confirm I have read and have abided by the ACCME standards for commercial support and the general principles of the EACCME Criteria for the Accreditation of Live Educational Events (LEEs) about presenting content without commercial bias.
  6. I affirm I am submitting an original abstract that has not been submitted elsewhere.
  7. The INS and the Organizers reserve the right to remove from any publication an abstract that does not comply with the above.
  8. I herewith confirm that the contact details saved in this system are those of the presenting author, who will be notified about the status of the abstract. The presenting author is responsible for informing the other authors about the status of the abstract.
  9.  I understand that the presenting author must be a registered participant.
  10. I understand that I must select a specific topic and presentation preference for my abstract allocation. Although the scientific committee will work hard to honor this selection, this cannot be guaranteed. The scientific committee reserves the right to change the topic and presentation under which the abstract was originally submitted.

NB: Submitted abstracts cannot be modified or corrected after the submission deadline (Wednesday, 2 December, 2020 – 23:59 CET)

Abstract-related questions can be directed to the Congress Secretariat.